MBX Biosciences Execs to Present at Three November Investor Conferences

  • MBX Biosciences CEO Steve Hoerter and CMO Sam Azoulay to present at Guggenheim, UBS, and Jefferies investor conferences in November 2026.
  • Fireside chats and 1x1 meetings scheduled at each event, with live webcasts available on the company's investor relations website.
  • Company advancing pipeline including canvuparatide (MBX 2109) in Phase 3 for chronic hypoparathyroidism and obesity portfolio candidates.
  • MBX Biosciences based in Carmel, Indiana and Burlington, Massachusetts.

MBX Biosciences' participation in multiple high-profile investor conferences underscores its push to engage with the investment community amid a critical phase of clinical development. The company's focus on precision peptide therapies aligns with broader industry trends toward targeted treatments for metabolic disorders, but its ability to stand out in a crowded field will be key. The upcoming presentations offer a platform to showcase pipeline progress and attract potential partners or investors.

Pipeline Progress
How the Phase 3 advancement of canvuparatide and Phase 1 progress of MBX 4291 will impact investor sentiment and valuation.
Market Positioning
Whether MBX Biosciences can differentiate itself in the competitive endocrine and metabolic disorders space.
Execution Risk
The pace at which the company can translate its proprietary PEP™ platform into commercial successes.